Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)
Information source: Abbott
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Trandolapril (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Abbott Official(s) and/or principal investigator(s): Global Medical Information 1-800-633-9110, Study Director, Affiliation: Abbott
Summary
The TRAIL study was conducted to examine the effects of escalating doses of an ACE
inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.
Clinical Details
Official title: A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL)
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Effectiveness of escalating dose regimen of trandolapril in controlling blood pressure
Secondary outcome: Changes in blood pressure, safety.BP mmHg incremental and absolute change Adverse events
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Stage 1 or 2 Hypertension
Exclusion Criteria:
- Uncontrolled diabetes
- Subject has a hypersensitivity to ACE inhibitor
Locations and Contacts
Additional Information
Starting date: March 2004
Last updated: July 18, 2008
|